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Peripheral node addressin (PNAd) marks high endothelial venules (HEV), which are 
crucial for the recruitment of lymphocytes into lymphoid organs in non-mucosal tissue 
sites. PNAd is a sulfated and fucosylated glycoprotein recognized by the prototypic 
monoclonal antibody, MECA-79. PNAd is the ligand for L-selectin, which is expressed 
on the surface of naive and central memory T cells, where it mediates leukocyte rolling on 
vascular endothelial surfaces. Although PNAd was first identified in the HEV of peripheral 
lymph nodes, recent work suggests a critical role for PNAd in the context of chronic 
inflammatory diseases, where it can be used as a marker for the formation of tertiary 
lymphoid organs (TLOs). TLO form in tissues impacted by sustained inflammation, such 
as the tumor microenvironment where they function as local sites of adaptive immune 
cell priming. This allows for specific B- and T-cell responses to be initiated or reactivated 
in inflamed tissues without dependency on secondary lymphoid organs. Recent studies 
of cancer in mice and humans have identified PNAd as a biomarker of improved disease 
prognosis. Blockade of PNAd or its ligand, L-selectin, can abrogate protective antitumor 
immunity in murine models. This review examines pathways regulating PNAd biosyn-
thesis by the endothelial cells integral to HEV and the formation and maintenance of 
lymphoid structures throughout the body, particularly in the setting of cancer.
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PATHwAYS ReGULATinG PnAd eXPReSSiOn
Signaling Through the Lymphotoxin Beta Receptor is Required 
for Hev Differentiation
Lymphotoxin beta receptor (LTβR) signaling drives expression of adhesion molecules and 
chemokines involved in the recruitment of circulating lymphocytes into lymphoid organs, including 
CCL21, CXCL13, MAdCAM-1, and peripheral node addressin (PNAd) (1). Specifically, expression 
of LTβR on endothelial cells in peripheral lymph nodes is required for their development into high 
Abbreviations: BGC, germinal center B cell; BV, blood vessel; cDC, conventional dendritic cell; fDC, follicular dendritic 
cell; Gal, galactose; GalNAc, N-acetylgalactosamine; GlcNAc, N-acetylglucosamine; HEC, high endothelial cell; HEV, high 
endothelial venule; HVEM, herpes virus entry mediator; PNAd, peripheral node addressin; SA, sialic acid; SLO, secondary 
lymphoid organ; TLO, tertiary lymphoid structure; TME, tumor microenvironment; TNFR, tumor necrosis factor receptor; 
VSMC, vascular smooth muscle cell.
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endothelial venules (HEV), with high endothelial cells (HEC) 
functioning as lymphoid tissue organizer (LTo) cells. Endothelial 
cell-specific deletion of LTβR leads to a reduction in: (i) MECA-
79 staining, (ii) CCL19, CCL21, and GlyCAM-1 expression, and 
(iii) the ability to assume cuboidal morphology by endothelial 
cells in peripheral lymphoid organs [Figure  1A; (2)]. In vivo 
work using bone marrow chimeric mice deficient in LTα in their 
hematopoietic compartment also implicates a role for LTβR-
mediated signaling in the maintenance of HEV, as these mice 
exhibit profoundly reduced lymph node cellularity (3).
LTα1β2 and LIGHT can bind and signal through the LTβR, 
while a related ligand, LTα3, can signal through TNFRI, TNFRII, 
and HVEM. All three ligands can be produced by CD11c+ DC 
(3). However, each ligand appears to have a distinct role in regu-
lating PNAd expression. In secondary lymphoid organs (SLO), 
LIGHT appears to have little impact on PNAd expression (4). 
Using a transgenic model of lymphotoxin overexpression in the 
pancreas, it was observed that LTα and LTβ play distinct roles in 
the formation of tertiary lymphoid organs (TLOs). LTα1β2 con-
trols luminal PNAd expression, while LTα3 controls abluminal 
PNAd expression (1). These differences in ligand function appear 
to relate to their impact on the level of GlcNAc6ST expression by 
endothelial cells. GlcNAc6ST-2 expression was reduced if only 
LTα, but not LTβ, was present, with HEV in LTβ−/− animals (that 
retained GlcNAc6ST-2) expressing PNAd (1). LTα−/− animals 
were deficient in GlcNAc6ST-2 expression on HEV, although 
they retained PNAd expression (5). Blockade of LTβR signaling 
also decreases transcription of GlcNAc6ST-2 in lymph nodes 
by 10-fold, with GlcNAc6ST-1, FucT-VII, and FucT-IV levels 
also coordinately reduced, thereby limiting posttranslational 
modification of PNAd and inhibiting its ability to be recognized 
by L-selectin (4).
Lymphocytes are also able to secrete lymphotoxin ligands 
(2, 4). Interestingly, the requirement for T or B cells themselves in 
HEV activation in SLO is equivocal. Reports suggest that neither 
cell type is required for HEV differentiation (4), although it has 
also been observed that Rag−/− mice exhibit decreased expression 
of GlcNAc6ST-2 compared to WT mice (6).
Posttranslational Modifications Are 
Required for L-Selectin Recognition  
of PnAd
Members of the PNAd family of addressins include GlyCAM-1, 
CD34, sgp200, podocalyxin, endomucin, and nepmucin: however, 
not all PNAd ligands appear to be required for lymphocyte traf-
ficking (7, 8). For example, lymphocyte trafficking to peripheral 
lymph nodes remains unaltered in CD34−/− (9) or GlyCAM1−/− 
(10) mice, suggesting redundancy in the functional roles of PNAd 
family members. In order for PNAd to be recognized by MECA-
79 as well as its receptor, L-selectin, a series of posttranslational 
modifications must first occur (Figure  1). Specifically, while 
PNAd undergoes sulfation and glycosylation (11), it is sulfation of 
the 6 sialyl Lewis X motif that renders these molecules recogniz-
able by the MECA-79 antibody (12). Fucosylation of the Core 
2 branched O-glycan serves as the recognition site of PNAd by 
L-selectin (Figure 1B) (13, 14).
Sulfation
GlcNAc6ST-1 and GlcNAc6ST-2 are members of the GalNAc6ST-
6-O-sulfotransferase subfamily of glycosyl sulfotransferases that 
are critical to the transfer of sulfate groups to galactose or GlcNAc 
at the sixth position, with this sulfation of carbohydrate motifs on 
PNAd required for it to be presented at the cell surface and to be 
recognized by the MECA-79 antibody and by its natural ligand, 
L-selectin (15).
Though related, GlcNAc6ST-1 and GlcNAc6ST-2 have differ-
ent roles in the sulfation of PNAd. Using mice deficient in either 
single sulfotransferase, it was shown that GlcNAc6ST-2 controls 
luminal expression of PNAd while GlcNAc6ST-1 controls expres-
sion of PNAd on the abluminal vascular surface (16, 17).
GlcNAc6ST-2 is expressed by mature, but not immature, HEV. 
Using a Cre-recombinase model, Kawashima and colleagues 
observed that expression of GlcNAc6ST-2 is activated in HEV cells 
recognized by the MECA-79 antibody (i.e., expressing PNAd), 
but not in cells reactive only with the MECA-367 antibody (rec-
ognizing MAdCAM-1) (18). This is consistent with observations 
that GlNAc6ST-1 and -2 have little impact on cellular expression 
of MAdCAM-1, a canonical marker of immature HEV in SLO 
within non-mucosal tissue sites (19).
Glycosylation
A family of α-(1,3)-fucosyltransferases control the fucosulation 
of E-, P-, and L-selectin ligands (20). In particular, FucT-VII and 
FucT-IV play distinct roles in the generation of L-selectin ligands 
on the surface of HEV. FucT-IV is required for the expression of 
L-selectin ligands on the surface of HEV, whereas the primary 
role of FucT-VII appears to be in its contribution to enhancing 
GlyCAM-1-mediated tethering of rolling lymphocytes. The 
specific role of FucT-VII temporally follows glycosylation and 
sulfation of the glycoprotein and is involved in capping the mol-
ecule to produce the preferred ligand recognized by L-selectin. 
Double knockout of both FucT-VII and FucT-IV in mice reduced 
lymphocyte recruitment to SLO by over 80% when compared to 
FucT-VII−/− mice (21).
MARKeRS OF HiGH  
enDOTHeLiAL venULeS
Two sets of adhesion molecules dominantly modulate lympho-
cyte recruitment to SLO/TLO depending upon which site in the 
body the cells are trafficking to: recruitment to peripheral lymph 
nodes is dependent upon the L-selectin–PNAd interaction, 
while recruitment to mucosal sites requires the α4β7 integrin–
MAdCAM-1 interaction (22). The same HEC that express PNAd 
or MAdCAM-1 also express CCL21, a CCR7 ligand. Supporting 
the importance of PNAd- and CCL21-expressing HEV for the 
recruitment of lymphocytes, the majority of lymphocytes in 
HEV-expressing tissues are spatially located within approxi-
mately 20 μm of HEV (23). CCL21 preferentially recruits CCR7+ 
CD4+ L-selectin+ (naive) T cells, which can interact with PNAd 
on the cells of the HEV. CCL21, like PNAd, is under the control 
of intrinsic LTβR-mediated signaling during HEV development 
(but not in mature lymphoid tissues) (1, 4).
FiGURe 1 | PnAd biosynthesis. (A) (1) LTβR is expressed on blood vessel endothelial cells. Membrane-bound LTα1β2 or secreted LTα3 secreted from cDC can 
signal through this receptor. (2) LTβR-mediated signaling promotes a physical change in vascular endothelial cells from a flat to cuboidal morphology. This signaling 
cascade also leads to the expression of PNAd on the surface of vascular endothelial cells, promoting HEV status. (3) LTβR signaling further induces HEV secreted 
chemokines, including CCL19, CCL21, and CXCL13. (4) Chemokines form gradients and “decorate” the blood vessel wall, initiating the recruitment of CCR7+ T cells 
or CXCR5+ B lymphocytes from the peripheral blood circulation into chronically inflamed tissues. (5) L-selectin on the surface of T cells is able to bind PNAd on the 
surface of HEV. These cells are then able to adhere to the vessel wall and extravasate into the tissue. (B) PNAd is synthesized from a Core 1 O-glycan. The 
extended Core 1 O-glycan serves as the MECA-79 recognition motif. The fucosylated Core 2 O-glycans are able to be recognized by L-selectin. Sulfation of the 
extended Core 1 and Core 2 O-glycans at the sixth position is mediated by GlcNAc6ST-1 and -2; α3 fucosylation is added by FucT-IV and -VII.
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FiGURe 2 | Structure of classical and non-classical tertiary lymphoid organs. (A) Classical TLO contain a nucleated core of fDC and germinal center B cells 
(BGC), surrounded by an HEV-containing T cell zone. (B) Non-classical TLO do not contain fDC or BGC, but may contain sparse B cell, T cell, and DC infiltrates 
surrounding HEV.
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iMMUne CeLL ReCRUiTMenT BY Hev
Peripheral node addressin binds L-selectin (aka CD62L or 
LECAM-1) expressed on the surface of lymphocytes. This inter-
action is required for the recruitment of lymphocytes into SLO 
(24). Posttranslational modifications of PNAd family members 
are critical for this interaction. For example, B cell recruitment 
to peripheral lymph nodes is dependent on sulfation of PNAd 
(19). The velocity of T and B cell rolling is also dependent upon 
sulfation of L-selectin ligands on lymph node endothelial cells, 
with adherence of lymphocytes to the vessel wall decreased in 
GlcNAc6ST-deficient animals (19). This may also be controlled 
by the presence of DC within SLO, as the velocity of lymphocyte 
rolling in CD11c-DTR mice was significantly increased, and the 
percentage of lymphocytes able to adhere to the vessel wall was 
decreased, in these mice after treatment with diphtheria toxin to 
delete DC. The HEV of DC-depleted mice regained expression of 
MAdCAM-1, and after reconstitution with adoptively transferred 
CD11c+ DC, these HEV recovered classical cuboidal morphol-
ogy, suggesting that DC-produced factor(s) is/are required for the 
maturation of HEV (3).
The CCR7–CCL21 axis is also important for lymphocyte 
recruitment into lymphoid organs. Mice deficient in CCR7 
have impaired migration of B and T cells, as well as DC, to SLO 
including lymph nodes and Peyer’s patches. This limits primary 
immune responses against infectious agents (25). Expression 
of CCL21 by HEC is controlled by a pathway unique to these 
cells versus HEC expressing alternate addressins. Specifically, 
heparan sulfate, a glycosaminoglycan primarily found on the 
surface of vascular endothelial cells, is required for CCL21 
expression on HEV (26). Using an Ext1-flox/flox mouse crossed 
with a GlcNAc6ST-2-cre transgenic mouse to delete a glyco-
syltransferase necessary for the synthesis of heparan sulfate in 
PNAd-expressing cells, expression of CCL21 on the surface of 
HEV was abrogated (23).
TeRTiARY LYMPHOiD ORGAnS
Although the pioneering work identifying PNAd and the 
pathways controlling its expression were initially studied in the 
context of SLO, recent literature supports an important role for 
PNAd in TLO (aka ectopic lymphoid structures) that develop 
in peripheral tissue sites impacted by chronic inflammation. 
Overall, TLOs have varying degrees of similarity to SLO. Classical 
TLO closely resembles SLO in their cellular composition, with 
TLO containing a network of follicular dendritic cells (fDC) and 
germinal centers in which B cells reside, proliferate, and differen-
tiate (Figure 2A). Non-classical TLO also contain some degree 
of B cell infiltration, but they do not exhibit an fDC “framework” 
(27), with only diffuse, sparse B cell distributions being observed 
(Figure 2B) (28–30).
The L-selectin–PNAd interaction controls lymphocyte recruit-
ment to TLOs. In particular, PNAd upregulation in affected 
tissues is observed in the settings of allergic contact dermatitis, 
lymphoid hyperplasia, and a variety of types of skin lesions and 
cutaneous lymphomas, i.e., diseases characterized by robust 
lymphocytic infiltrates into peripheral tissues (31). The CCR7 
signaling axis also plays a role in TLO formation. Most impor-
tantly, CCR7-mediated signals are required for the clustering of 
DC in peripheral tissues. Interactions between DC and T cells 
proximal to blood vessels appears required for the acquisition of 
PNAd + HEV in peripheral tissues (5).
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Notably, LTβR-mediated signaling controls the formation of 
HEV in peripheral tissues (5, 32). Akin to the roles that lympho-
toxin signaling plays in the control of PNAd expression in SLO, 
LTα3-dependent signaling has been reported to dominantly con-
trol PNAd expression on HEV within the tumor microenviron-
ment (TME) in murine melanoma models (32), while in human 
breast cancer, LTβ (produced by DC-LAMP + DC) appears to 
play a comparable dominant role (33).
Tertiary lymphoid organs have been observed in a variety of 
chronic inflammatory diseases, including arthritis (34), gastritis 
and ulcerative colitis (13, 35), atherosclerosis (36), and cancer 
(37). As the development of TLO in chronic/autoimmune dis-
eases has been well-reviewed (38, 39), we will now focus on the 
emerging field of TLO formation in solid tumors.
TLO in Cancer
Cancer-associated TLO characteristically contain PNAd+ vessels 
and are commonly localized to the outer margin (versus the 
core) of the tumor lesion (40). With the exception of reports 
for TLO predicting a worse prognosis in patients with renal cell 
carcinoma (RCC) (41) and some cases of colorectal cancer (42), 
the vast weight of the literature has correlated the presence of 
TLOs in human solid tumors with better clinical prognoses (43). 
Both classical and non-classical TLO have been reported within 
the TME (Figure 2). Of these two forms of TLO, however, the 
presence of classical TLO in tumors may provide a superior index 
for improved prognosis when compared to the presence of only 
non-classical TLO in the TME (27). These results suggest that 
systematic analysis of PNAd expression and TLO status in tumor 
biopsies may be a useful in addition to current clinical criteria 
used to predict patient outcomes.
Lung Cancer
In non-small-cell lung cancer (NSCLC), PNAd+ vessels have 
been identified exclusively within TLO (44). In these tumors, 
the composition of cells within the TLO specifically correlates 
with patient prognosis. While T cells (all tumor-infiltrating 
L-selectin+ T cells, comprised of both naive and central memory 
CD4+ and CD8+ cells) are localized to TLO (44, 45), overall 
T cell infiltrate and density appears to play a minor role in patient 
outcome when evaluated independently of other prognostic 
markers. Instead, the density and proximity of mature DC to 
TLO within the tumor may be most important, and patients with 
high DC-LAMP+ mDC infiltrates exhibit markedly extended 
overall survival (45). These findings are further supported by 
gene array data indicating that CXCR4, a gene associated with 
DC migration toward CXCL12 gradients, is strongly correlated 
with increased overall survival in NSCLC patients (46). Unlike 
T  cells, B cells do appear to play a significant protective role 
against lung cancer, and their presence can be used as a positive 
prognostic marker of overall survival. Interestingly, DC and 
B cell density in TLO can be used as a coordinate prognostic 
marker for patients with greatest overall survival. In NSCLC, B 
cells organize into germinal center-like structures containing 
CD21+ fDC. These B cells proliferate and differentiate in  situ, 
leading to locoregional secretion of IgG and IgA antibodies 
 reactive against tumor-associated antigens (47).
Skin Cancers
Tertiary lymphoid organs have been identified in both primary 
and metastatic melanoma, where they have been observed to 
contain PNAd+ vessels (48, 49). TLO in primary melanomas 
can be either classical or non-classical TLO. In metastatic 
melanoma, these structures are primarily composed of CD3+ 
T cells and mature (DC-LAMP+) DC proximal to PNAd+ HEV 
(50). Plasma B cells may also be present in such TLO, with these 
cells producing Th-dependent IgG and IgA antibodies specific 
for tumor-associated antigens (48, 50). In primary cutaneous 
melanoma, the presence of intratumoral HEV has been cor-
related with robust lymphocytic infiltration and tumor regres-
sion. Furthermore, if the HEC making up HEV have a cuboidal 
morphology, indicative of functional HEV, a positive correlation 
with CCR7, CCL19, and CCL21 expression within the tumor has 
also been observed (51).
The presence of TLO also portends better clinical outcome 
(recurrence free and overall survival) in the setting of Merkel 
cell carcinoma. These structures are also characterized by an 
increased CD8+/CD4+ T cell ratio at the tumor periphery and by 
a co-clustering of T and B cells within these anatomic sites (52).
Colon Cancer
Tertiary lymphoid organs in human colon cancer have been 
detected in both the colon crypt and at the invasive front of 
the tumor, as well as in the peritumoral region (53, 54). They 
contain immune cell types typically observed in SLO, includ-
ing B cells, CD21+ fDC, T cells, and mature DC marked by 
DC-LAMP+, with CD31+ vascular endothelial cells and LYVE-
1+ lymphatic vessels also noted (53, 54). T cells and mature DC 
represent positive prognostic markers in both primary (43) and 
metastatic (41) colorectal cancer. In such tumors, the B cells 
may not organize into germinal center-like structures (53, 54). 
These TLO appear to function as local sites for the priming and 
expansion of both B and T cells, based on the expression of 
the Ki-67 marker in de facto germinal centers in these diseased 
tissues (54).
Therapeutic Induction of TLO
Recent work from our group suggests that intratumoral TLO 
can be induced therapeutically via adoptive transfer of gene-
modified DC, leading to reduced tumor progression. Following 
intratumoral injection of Type 1-polarized DC (DC engineered 
to overexpress Tbet, i.e., DC.Tbet) into established murine sar-
comas or colon carcinomas, CD4+ and CD8+ T cell recruitment 
to the TME is observed within 2 days, with an upregulation of 
PNAd expression detected by 5 days after treatment. This suggests 
that PNAd-independent events control early T cell recruitment 
to the TME, and that T cell-dependent factors may consequently 
result in PNAd upregulation on tumor-associated VEC (28, 29). 
Once established, PNAd+ vessels become surrounded by dense 
infiltrates of both CD11c+ DC and CD3+ T cells, with these non-
classical TLO principally localized near the tumor periphery for 
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at least 2 weeks following initial therapeutic intervention (28, 29). 
The presence of DC in TLO is consistent with prior studies of 
SLO demonstrating that DC accumulation proximal to HEV is 
required for the subsequent optimal homing of lymphocytes into 
SLO (3).
FUTURe PeRSPeCTiveS
Although there appears to be some variability in the cellular 
composition across tumor types, TLO in the TME contain PNAd+ 
HEV typically surrounded by dense B cell and/or DC infiltrates. 
Importantly, the presence of intratumoral or peritumoral TLO 
has been almost universally linked with superior clinical progno-
sis in patients with solid forms of cancer. Though T cells are also 
present in intratumoral TLO, their presence has thus far proven 
equivocal as a prognostic biomarker. The spontaneous formation 
of TLO has been observed in a variety of human cancers, includ-
ing those reviewed above as well as oral squamous cell carcinoma 
(27, 55), gastric cancer (40, 56), bladder cancer (57), breast cancer 
(30, 58, 59), and others (37, 60). Thus, it may ultimately be best 
to employ PNAd as well as B cell and DC infiltration in the TME 
as biomarkers to stratify patients based on TLO status, i.e., to 
differentiate individuals that may respond better to treatment 
intervention, including immunotherapies (based on superior 
locoregional immune competency). Furthermore, because TLO 
may be induced therapeutically (at least in murine models), it is 
also intriguing to speculate on the possibility that protective TLO 
may be conditionally sponsored in patients receiving chemo- or 
immunotherapies (61), and that such structures may be used to 
monitor/predict the patient’s outcome and prospective treatment 
management.
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